As the frequency of CD160‐expressing CD8+ T cells in PBMC populations is higher in esophageal cancer patients than in normal donors216 and CD160 expression levels are increased on CD8+ T cells from bone marrow of multiple myeloma versus healthy patients,217 this checkpoint receptor might also be a useful target for ICB therapy against certain cancer types. The gene discussed is CD8A; the disease is plasma cell myeloma.